Turing Pharmaceuticals, the drug company helmed by Martin Shkreli, is planning to cut the price of its drug Daraprim by as much as 50%, according to The Wall Street Journal.
Shrkeli was the subject of wide-spread public ire in September when he raised the price of the anti-parasite drug from $US13.50 a tablet to $US750 a tablet.
The increase was so controversial it prompted anger from Democratic presidential candidates Bernie Sanders and Hillary Clinton, and legislators have called Shkreli to Washington to explain his business practices.
Daraprim’s price increase also brought attention to price increases across the pharmaceutical industry. The Senate has launched a bipartisan investigation into the matter.
Shkreli declined to comment when contacted by Business Insider late Friday. He told Business Insider earlier this month that there would be a modest decrease in the price of Daraprim by Christmas.
“We’ll announce when we announce,” he said at the time.
The Daraprim discount will depend on how much of the drug a hospital uses, according to the WSJ. The report added that out-of-hospital users will not be able to get a discount, and will still have to depend on insurance companies to cover the cost of the drug.